Purpose: To evaluate the incidence of intraocular pressure (IOP) spikes within the first postoperative hours following trabeculectomy (TRAB) and to determine possible associated factors. Methods: An observational study was carried out. We enrolled consecutive patients undergoing standard TRAB with mitomycin C. They were examined twice within the first few postoperative hours (hours 1-2 and 4-6) and 3 times after TRAB (on days 1, 7, and 30). Demographic and ocular data were collected. Main outcome measurements were postoperative IOP values at each time point and the frequency of IOP spikes, defined as IOP ≥25 mm Hg. Results: A total of 40 eyes of 40 patients were included (mean age 59.62 ± 13.37 years). Although IOP was significantly reduced to 11.14 ± 7.99 mm Hg at hours 1-2 (p < 0.01) and to 11.52 ± 7.30 mm Hg at hours 4-6 (p < 0.01), IOP spikes were documented in 3 patients (7.5%). In the group of patients with IOP spikes, we noted that there was a high incidence of black patients and that the surgeries had been performed by fellow surgeons. Conclusion: Although the majority of the cases (92.5% of the patients) did not present IOP spikes, 7.5% of our patients presented the event. In selected cases, such as those with advanced disease, fixation threat, and of black race, IOP should be monitored during the first few postoperative hours for the identification and adequate management of potential IOP spikes, preventing undesirable outcomes.

Keywords:
Glaucoma surgery, Trabeculectomy, Trabeculectomy adverse effects, Intraocular pressure spike, Advanced glaucoma
1.
Weinreb RN, Khaw PT: Primary open-angle glaucoma. Lancet 2004;363:1711-1720.
2.
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group: Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-1279.
3.
AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-440.
4.
Boland MV, Ervin AM, Friedman DS, Jampel HD, Hawkins BS, Vollenweider D, Chelladurai Y, Ward D, Suarez-Cuervo C, Robinson KA: Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2013;158:271-279.
5.
Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO: The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-713; discussion 829-830.
6.
Weinreb RN, Aung T, Medeiros FA: The pathophysiology and treatment of glaucoma: a review. JAMA 2014;311:1901-1911.
7.
Shigeeda T, Tomidokoro A, Araie M, Koseki N, Yamamoto S: Long-term follow-up of visual field progression after trabeculectomy in progressive normal-tension glaucoma. Ophthalmology 2002;109:766-770.
8.
Addicks EM, Quigley HA, Green WR, Robin AL: Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol 1983;101:795-798.
9.
Khaw PT, Ward S, Grierson I, Rice NS: Effect of beta radiation on proliferating human Tenon's capsule fibroblasts. Br J Ophthalmol 1991;75:580-583.
10.
Miller MH, Rice NS: Trabeculectomy combined with beta irradiation for congenital glaucoma. Br J Ophthalmol 1991;75:584-590.
11.
Inatani M, Tanihara H, Muto T, Honjo M, Okazaki K, Kido N, Honda Y: Transient intraocular pressure elevation after trabeculotomy and its occurrence with phacoemulsification and intraocular lens implantation. Jpn J Ophthalmol 2001;45:288-292.
12.
Takihara Y, Inatani M, Ogata-Iwao M, Kawai M, Inoue T, Iwao K, Tanihara H: Trabeculectomy for open-angle glaucoma in phakic eyes vs in pseudophakic eyes after phacoemulsification: a prospective clinical cohort study. JAMA Ophthalmol 2014;132:69-76.
13.
Biggerstaff KS, Vincent RD, Lin AP, Orengo-Nania S, Frankfort BJ: Trabeculectomy outcomes by supervised trainees in a Veterans Affairs Medical Center. J Glaucoma 2016;25:669-673.
14.
Kim SH, Lee EJ, Han JC, Sohn SW, Rhee T, Kee C: The effect of diurnal fluctuation in intraocular pressure on the evaluation of risk factors of progression in normal tension glaucoma. PLoS One 2016;11:e0164876.
15.
AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS). 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. Am J Ophthalmol 2002;134:481-498.
16.
Chen PP, Musch DC, Niziol LM: The effect of early posttrabeculectomy intraocular pressure spike in the Collaborative Initial Glaucoma Treatment Study. J Glaucoma 2011;20:211-214.
17.
Taubenslag KJ, Kammer JA: Outcomes disparities between black and white populations in the surgical management of glaucoma. Semin Ophthalmol 2016;31:385-393.
18.
Fernández Argones L, Padilla González CM, Obret Mendive I, Piloto Díaz I, Fumero González FY: Prognostic factors for trabeculectomy failure in a Cuban population (in English, Spanish). Arch Soc Esp Oftalmol 2016;91:27-33.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.